What Juvenescence does

Juvenescence is a clinical-stage AI-enabled biotechnology company developing medicines that target core mechanisms of aging to treat and prevent age-related diseases rather than individual disease symptoms. Its pipeline spans five core therapeutic candidates: a PAI-1 inhibitor (MDI-2517) advancing to Phase 2 in chronic kidney disease and fibrotic lung disease, a CD38 inhibitor (NTX-748) targeting NAD metabolism and cognitive aging, a GDF-15 monoclonal antibody for cardio-metabolic conditions, plus Ketone Rx and Plasmalogen candidates. Underpinning the pipeline is the proprietary JuvAI platform, which combines JuvAI Biology (an LLM-enabled biomedical knowledge graph with 85 million nodes and 400 million relationships), JuvAI Chemistry (point-cloud ML and a 3D variational GAN for molecular design), and JuvAI Clinic (adaptive clinical trial optimization). Nine granted patents protect core platform components.

The company operates a dual model combining internal pipeline development with a strategic portfolio of minority investments in adjacent platform companies, including Relation Therapeutics ($1.7B Novartis collaboration), LyGenesis (Phase 2a liver cell therapy), Morphoceuticals, Chrysea (Sprevive spermidine supplement), MDI Therapeutics, Serina Therapeutics, Napa Therapeutics (joint venture with Buck Institute and Insilico Medicine), and others. Juvenescence has cumulatively raised roughly $295M+ across multiple private rounds, most recently a $76M Series B-1 led by Abu Dhabi-based M42 in May 2025, and acquired AI-drug-discovery company Ro5 Inc. in June 2025. The company is incorporated in the Isle of Man, operates primarily from the UK with an EU data controller entity in Dublin, and is expanding into the UAE through new research offices at Masdar City, Abu Dhabi, alongside a partnership providing access to the Emirati Genome Project's 800,000+ whole genomes. Leadership includes CEO Dr. Richard Marshall CBE (appointed January 2023), CTO Eileen Jennings-Brown (appointed February 2026), CSO Gill Dines, and co-founders Jim Mellon, Dr. Greg Bailey, and Dr. Declan Doogan.

Juvenescence is pre-revenue and does not yet have commercialized products or public pricing. Its business model is built on eventual monetization through licensing, co-development partnerships, or acquisition by large pharmaceutical companies, as exemplified by portfolio company Relation Therapeutics' Novartis and GSK deals. Customer relationships today are essentially institutional: M42 functions as both lead investor and strategic partner, the Buck Institute as a research collaborator, Masdar City as an infrastructure host, and large pharma as the prospective future acquirer or licensee of pipeline assets. Marketing and commercial development are conducted through scientific conferences, industry forums (including The Longevity Forum in London), investor relations communications, and selective media engagement rather than traditional sales channels.

Name

Juvenescence

Legal name

Juvenescence Limited

Website

https://juvlabs.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

Juvenescence is a clinical-stage, AI-enabled biotechnology company developing medicines that target core mechanisms of aging to treat and prevent age-related diseases, using its proprietary JuvAI platform and a portfolio of therapeutic and investment assets spanning cognition, cardio-metabolism, immunity, and cellular repair.

Ownership category

akta.pro rank

Product category

Longevity Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

akta.pro primary industry

Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)

akta.pro secondary industry

Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE)

Keywords

• AI drug discovery
• Longevity therapeutics
• Clinical-stage biotech
• Aging biology research
• Pharmaceutical development

Headquarters

HQ city

Dublin

HQ country

Ireland

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Therapeutic Development and Commercialization: Pre-revenue clinical stage company developing medicines targeting core aging mechanisms. Revenue will be generated through eventual commercialization of therapeutics upon regulatory approval, with potential for licensing, co-development partnerships, or acquisition by larger pharmaceutical companies.
2. Strategic Partnerships and Licensing: The company generates value through strategic partnerships with pharmaceutical companies (evidenced by portfolio company Relation Therapeutics' $1.7B Novartis collaboration and $300M GSK collaborations) and may pursue similar licensing deals for its own pipeline assets upon clinical validation.
3. Portfolio Company Returns: Investments in portfolio companies (Serina Therapeutics, Relation Therapeutics, LyGenesis, Morphoceuticals, Component Health, Chrysea, PerformAge, MDI Therapeutics, BYOMass, Souvien Therapeutics) may generate returns through equity appreciation, IPOs, or acquisitions of portfolio companies.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

Juvenescence is a clinical-stage biotech developing first-in-class therapeutics that target core mechanisms of aging to treat and prevent age-related diseases. Its pipeline includes PAI-1 Inhibitor (MDI-2517), GDF-15 monoclonal antibody, CD38 Inhibitor (NTX-748), Ketone Rx, and Plasmalogen candidates across cognition, cardio-metabolism, immunity, and cellular repair areas. Drug discovery is powered by the proprietary JuvAI platform combining a biomedical knowledge graph with AI/ML for molecular design and adaptive clinical trials.

Product overview

Juvenescence is a clinical-stage AI-enabled biotech developing medicines to extend healthy lifespan by targeting core aging mechanisms. The company's core offering is the JuvAI integrated AI platform (JuvAI Biology, JuvAI Chemistry, JuvAI Clinic) powering a pipeline of five core medicines including PAI-1 Inhibitor (MDI-2517), GDF-15 mAb, CD38 Inhibitor, Ketone Rx, and Plasmalogen. The portfolio spans across cognition, cardio-metabolism, immunity, and cellular repair therapeutic areas. Juvenescence operates a strategic portfolio model with investments in platform technologies and companies including Serina Therapeutics (drug delivery), Relation Therapeutics (AI biology), LyGenesis (organ regeneration), Morphoceuticals (bioelectrome), Chrysea (nutritional supplements via Sprevive), and PerformAge (digital health). The company was founded by Jim Mellon, Dr. Greg Bailey, and Dr. Declan Doogan, with leadership by Dr. Richard Marshall CBE, and maintains operations in the UK, UAE (Masdar City), and Ramsey, Isle of Man.

Differentiator

Problem solved

Functional benefit

Brands

• JuvAI: Fully integrated AI system spanning JuvAI Biology (LLM-enabled biomedical knowledge graph), JuvAI Chemistry (AI/ML platform for molecular design and optimization), and JuvAI Clinic (ML tools for adaptive clinical trials and precision patient selection).
• JuvTherapeutics
• Sprevive

Products and services

• JuvAI Platform Integrated AI system for drug discovery spanning target selection to clinical trials, comprising JuvAI Biology, JuvAI Chemistry, and JuvAI Clinic modules. Used internally by Juvenescence to advance its aging-targeting therapeutic pipeline.
• PAI-1 Inhibitor (MDI-2517) First-in-class PAI-1 inhibitor drug candidate targeting fundamental aging mechanisms. Demonstrated safety and tolerability in Phase 1 trials for once-daily dosing and advancing to Phase 2 for chronic kidney disease and fibrotic lung disease.
• GDF-15 mAb

Quantifiable outcome

• PAI-1 inhibitor (MDI-2517) demonstrated safety, tolerability, and suitability for once-daily dosing in Phase 1 trials, advancing to Phase 2 for chronic kidney disease and fibrotic lung disease
• +3 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature10 records

Partnerships

Twelve partnerships are on record, tiered core and portfolio.

• Masdar CitycoreStrategic or Co-development Partner · 16 February 2026Abu Dhabi's premier life sciences and biotechnology hub providing world-class infrastructure, proximity to leading regional research institutions, government-backed initiatives from Abu Dhabi Department of Health and Abu Dhabi Investment Office, and access to growing biotech community. Juvenescence establishing Advanced AI Drug Discovery Laboratory at this location.
• Emirati Genome ProjectcoreOthersUAE's national genomic initiative providing access to 800,000+ whole genomes dataset. Enables Juvenescence to leverage unprecedented genomic and health data for precision medicine development and clinical trial acceleration through M42 partnership.
• Buck Institute for Research on AgingcoreStrategic or Co-development PartnerLeading research institution focused solely on aging research. Ongoing collaboration with Dr. Eric Verdin's lab on CD38 inhibitor program (NTX-748) for cognitive decline in aging. Dr. Verdin presented data showing CD38 inhibition may enhance cognitive performance by modulating NAD metabolism.
• Ro5 Inc.coreTechnology or IntegrationAcquired AI drug discovery company in June 2025. Enhanced Juvenescence's AI/ML drug discovery capabilities with proprietary Biomedical Knowledge Graph (85M+ nodes, 400M+ relationships) and AI Chemistry Platform. Critical component of M42 strategic partnership for AI-enabled drug discovery.
• Serina TherapeuticsportfolioOthersPortfolio company with foundational platforms based on proprietary Poly-oxazoline (POZ) technology for delivering small molecules and biologics.
• Relation TherapeuticsportfolioOthersPortfolio company with platform technology discovering relationships at the heart of biology. Lab-in-the-Loop approach combining human genetics, single cell multi-omics, functional assays and ML. Announced $1.7B strategic collaboration with Novartis for atopic diseases and $300M+ collaborations with GSK.
• LyGenesisportfolioOthersPortfolio company utilizing lymph nodes as in-vivo bioreactors to grow functioning ectopic organs. Lead cell therapy in Phase 2a for End-Stage Liver Disease with dose escalation approved.
• MorphoceuticalsportfolioOthersPortfolio company manipulating bioelectrome to induce regeneration and treat disease. Collaboration with Prof Michael Levin and Prof David Kaplan.
• ChryseaportfolioOthersPortfolio company and synthetic biology pioneer developing healthy nutritional interventions. Launched Sprevive - pure spermidine formulation using patented precision fermentation. Presented study results at Gordon Research Conference showing associations between higher spermidine intake and lower cardiovascular risk.
• PerformAgeportfolioOthersPortfolio company with proprietary digital health platform.
• MDI TherapeuticsportfolioOthersPortfolio company developing novel serpin-based therapies for fibrotic disease.
• Napa TherapeuticsportfolioStrategic or Co-development PartnerJoint venture with Buck Institute and Insilico Medicine established in 2018 to advance therapeutics targeting aging mechanisms.

Scale indicators9 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Insilico Medicine: AI-driven drug discovery company developing therapeutics for aging and age-related diseases. Directly comparable as both leverage generative AI and omics-based target identification to advance aging biology into the clinic, and Insilico is a co-founder of Juvenescence's Napa Therapeutics joint venture.
• Altos Labs: Well-capitalized ($3B) biotech pursuing cellular rejuvenation to reverse aging and age-related disease. Direct competitor for talent, partnership mindshare, and clinical proof-of-concept in the core aging-mechanism thesis Juvenescence is built on.
• Calico Life Sciences: Alphabet-backed longevity biotech targeting fundamental mechanisms of aging and age-related disease. Comparable as a deep-pocketed, long-horizon R&D organization pursuing similar biology with substantially greater capital.
• Unity Biotechnology: Clinical-stage biotech developing senolytic medicines to treat age-related diseases. Direct peer in modality (small molecules targeting aging biology) and indication space (ocular, musculoskeletal, pulmonary).
• BioAge Labs: AI-enabled biotech discovering and developing therapeutics that target molecular drivers of aging. Highly comparable as a clinical-stage, AI-native longevity company targeting core aging pathways with a similar partnership-driven business model.

Emerging players

• NewLimit: Early-stage company developing epigenetic reprogramming therapies to restore youthful function in aged cells. Comparable in its focus on core aging mechanisms but earlier-stage and focused on cellular reprogramming rather than small-molecule/mAb discovery.
• Loyal for Dogs: Developer of FDA-acknowledged longevity drugs (veterinary first). Comparable as a longevity therapeutics company pursuing regulatory pathways for aging intervention, but operates in animal health rather than human therapeutics.

Broad incumbents

• Exscientia: Larger AI-driven drug discovery company with a broader therapeutic-area focus. Comparable on the AI platform layer (Juvenescence's new CTO came from Exscientia) but Exscientia is a public, larger-scale pharma partner rather than a focused aging specialist.
• Recursion Pharmaceuticals: Publicly listed AI-enabled biotech combining high-throughput biology with machine learning for drug discovery. Comparable as an AI-native drug discovery peer but operates across many therapeutic areas with a much larger capital base.
• Schrödinger, Inc. Public computational chemistry and biology platform serving pharma R&D. Comparable in providing physics-based and ML drug discovery capabilities that overlap with Juvenescence's JuvAI Chemistry stack, but operates as a broad software-and-services platform rather than an aging-focused therapeutic developer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/juvenescence1

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries11 records

Funding overview

Funding rounds5 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments14 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Juvenescence